The fourth edition in this series reflects the medium-sized pharmaceutical industry, a sector that is highly attractive for investors. In doing so, we deliberately did not focus on global players with their blockbusters or vaccine manufacturers, who enjoy high general interest due to the COVID-19 pandemic and have high valuation values given the actual market outlook. But besides these market players, we see an enormous market for medium-sized market participants with interesting products and tremendous growth prospects.